Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bind Therapeutics Inc.

Division of Pfizer Inc.
www.bindtherapeutics.com

Latest From Bind Therapeutics Inc.

With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules

Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.

Commercial Companies

Biopharma Quarterly Dealmaking Statistics, Q3 2016

In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.

BioPharmaceutical Deals

Deal Watch: Medivation Enters Confidential Talks With Suitors, Including Sanofi

Bristol acquires Swedish biotech Cormorant to bolster its immuno-oncology franchise. Moderna quickly follows up its cancer partnership with another with Vertex to use mRNA approaches to treat cystic fibrosis.

Deals Commercial

Pfizer Jumps At The Chance To Apply Bind’s Technology To Immuno-Oncology

Bind has agreed to sell all of its assets to Pfizer for $19.75m after filing for bankruptcy in May. An auction is scheduled for July 25 if other bidders come forward.

Deals Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Bind Biosciences Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • Dan Koerwer, CBO
    Stephen Zale, PhD, VP, Discovery & Rsch.
    Christopher Lindblom, SVP, Fin. & Admin.
  • Contact Info
  • Bind Therapeutics Inc.
    Phone: (617) 491-3400
    325 Vassar St.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register